Novo Nordisk lifts 2026 outlook as Wegovy pill gains traction
Novo Nordisk lifted 2026 sales and profit guidance to -2% to +2%. Third-quarter sales beat estimates, while the Wegovy pill posted 5.39 billion kroner. Pricing and patent risks remain.
Topic
Novo Nordisk
Topic
Novo Nordisk
Novo's CagriSema Delivers 25% Weight Loss in Women in Late-Stage Trial
Novo Nordisk says its experimental CagriSema injection achieved 25% weight loss in women in a late-stage analysis, topping the re…
Novo Nordisk Strikes Second Licensing Deal After Rough Capital Markets Day
Novo Nordisk on Tuesday struck its second licensing deal since investors gave its long-term strategy a poor reception at its capi…
Novo's Wegovy Pill Delivers Further Weight Loss for Injection Switchers
Novo says patients switching from Wegovy or Zepbound injections to its new pill lost another 8.8 pounds on average in three month…
Lilly Claims 61% of US GLP-1 Market as Novo Bets $23B Pipeline
Lilly holds 61% of the U.S. GLP-1 market and is gaining in pills and Medicare. Novo counters with a $23 billion pipeline bet, but…
Lilly Claims 70% of 700,000 New Medicare GLP-1 Seniors
Eli Lilly CEO Dave Ricks says 700,000 seniors started GLP-1s since July's Medicare coverage launch — and 70% of them are on Lilly…
Eli Lilly Says One-Third of New GLP-1 Pill Patients Choose Foundayo
One-third of new GLP-1 pill patients pick Foundayo, CEO Dave Ricks says, as Lilly breaks ground on a $6.5 billion Houston plant d…